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Type 2 diabetes mellitus is a complex disorder encompassing multiple metabolic defects. We report results from
an autosomal genome scan for type 2 diabetes–related quantitative traits in 580 Finnish families ascertained for
an affected sibling pair and analyzed by the variance components-based quantitative-trait locus (QTL) linkage
approach. We analyzed diabetic and nondiabetic subjects separately, because of the possible impact of disease on
the traits of interest. In diabetic individuals, our strongest results were observed on chromosomes 3 (fasting C-
peptide/glucose: maximum LOD score [MLS] p 3.13 at 53.0 cM) and 13 (body-mass index: MLS p 3.28 at 5.0
cM). In nondiabetic individuals, the strongest results were observed on chromosomes 10 (acute insulin response:
MLS p 3.11 at 21.0 cM), 13 (2-h insulin: MLS p 2.86 at 65.5 cM), and 17 (fasting insulin/glucose ratio: MLS
p 3.20 at 9.0 cM). In several cases, there was evidence for overlapping signals between diabetic and nondiabetic
individuals; therefore we performed joint analyses. In these joint analyses, we observed strong signals for chro-
mosomes 3 (body-mass index: MLS p 3.43 at 59.5 cM), 17 (empirical insulin-resistance index: MLS p 3.61 at
0.0 cM), and 19 (empirical insulin-resistance index: MLS p 2.80 at 74.5 cM). Integrating genome-scan results
from the companion article by Ghosh et al., we identify several regions that may harbor susceptibility genes for
type 2 diabetes in the Finnish population.
Introduction
Type 2 diabetes is a heterogeneous disease character-
ized by insulin resistance and b-cell dysfunction (De-
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Fronzo 1987; Bergman 1989). Left untreated, the fast-
ing hyperglycemia can lead to a variety of secondary
complications, including retinopathy, nephropathy,
and neuropathy. Type 2 diabetes is also a risk factor
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for cardiovascular disease and hypertension (DeFronzo
and Ferrannini 1991; Harris 1990) and contributes sig-
nificantly to disease morbidity and mortality. Although
the clinical characteristics of type 2 diabetes are well
documented, the specific physiologic or biochemical de-
fects responsible for the pathogenesis of the disease
remain unclear. There is good evidence for a genetic
component to type 2 diabetes (Rich 1990; Ghosh and
Schork 1996). It is also clear that environmental factors
play a major role in disease pathogenesis.
Several groups have performed genome scans for type
2 diabetes, in attempts to identify disease-susceptibility
loci (Hanis et al. 1996; Mahtani et al. 1996; Hanson
et al. 1998; Imperatore et al. 1998; Pratley et al. 1998;
Duggirala et al. 1999; Elbein et al. 1999; Ghosh et al.
1999; Ehm et al. 2000). Although evidence has been
reported for chromosomal regions that may contain
type 2 diabetes–susceptibility genes, until recently only
genes for specific subtypes of type 2 diabetes, such as
maturity-onset diabetes of the young (MODY), have
appeared in the literature (Bell et al. 1991; Froguel et
al. 1992; Vaxillaire et al. 1995; Horikawa et al. 1997;
Stoffers et al. 1997). These relatively rare subtypes of
type 2 diabetes have been determined to be monogenic
in nature, and multiple studies suggest that these genes
play, at most, a minor role in genetic susceptibility for
the more general form(s) of type 2 diabetes (Hanis et
al. 1996; Mahtani et al. 1996; Elbein et al. 1999). Re-
cently, the chromosome 2 locus linked to type 2 diabetes
in Mexican Americans (Hanis et al. 1996) has been
cloned and identified as calpain-10 (Horikawa et al.
2000). This raises the possibility that additional type 2
diabetes–susceptibility genes might be cloned and iden-
tified in the near future.
In this article and the companion article (Ghosh et
al. 2000 [in this issue]), we describe genomewide re-
sults from the Finland–United States Investigation of
NIDDMGenetics (FUSION) study, a multicenter effort
to positionally clone genes for type 2 diabetes in the
Finnish population. As described in the companion ar-
ticle by Ghosh et al. (2000 [in this issue]), we recruited
and tested 580 families ascertained for an affected sib-
ling pair. An important component of FUSION was
the measurement of a variety of type 2 diabetes–related
quantitative traits in subjects with and without disease.
As part of our efforts to identify disease-predisposing
loci, we performed an autosomal genome scan using
these disease-related traits. The rationale behind this
approach is that, because the traits examined are
closely related to type 2 diabetes, any quantitative-trait
locus (QTL) that we identify may also act as a disease-
susceptibility or modifier locus. Coupled with the re-
sults from our type 2 diabetes genome scan (Ghosh et
al. 2000 [in this issue]), we identify along the genome
several regions that may harbor type 2 diabetes–sus-
ceptibility genes and that warrant further examination.
Subjects and Methods
Subjects and Phenotyping
The FUSION study design, recruitment, and pheno-
typing have been detailed elsewhere (Valle et al. 1998),
and details regarding genotyping can be found in the
companion article by Ghosh et al. (2000 [in this issue]).
Therefore, in this article we only briefly review recruit-
ment and phenotyping. Index cases were ascertained as
those with age at onset of 35–60 years and at least one
sibling diagnosed with type 2 diabetes. We successfully
recruited and phenotyped 580 families, each with a min-
imum of one affected sibling pair (ASP) but, whenever
possible, also collected additional siblings with type 2
diabetes. Two hundred ten of the families were also ex-
tended to include both a nondiabetic spouse and two or
more nondiabetic offspring of the index case and/or di-
abetic siblings.
For all subjects, we collected basic demographic, an-
thropometric, and extensive medical-history informa-
tion. Fasting glucose, insulin, lipids, and resting blood
pressure were measured in all study subjects. Fasting
C-peptide and glutamic acid decarboxylase antibody
(GAD Ab) were measured in diabetic individuals, and
these values were used in conjunction with insulin-treat-
ment information to identify possible cases of late-on-
set type 1 diabetes, as described elsewhere (Valle et al.
1998). An oral glucose-tolerance test (OGTT), conform-
ing toWorld Health Organization (1985) standards, was
performed both in all nondiabetic subjects, to determine
their glucose-tolerance status, and in diabetic subjects
whose affection status could not be readily confirmed,
yielding 2-h glucose and insulin measurements in these
individuals. Because of the small number of diabetic in-
dividuals who underwent the OGTT, 2-h glucose and
insulin data were analyzed only for the nondiabetic
subjects.
Nondiabetic spouses and offspring of either index
cases or diabetic siblings were also invited to undergo a
tolbutamide-modified frequently sampled intravenous
glucose-tolerance test (FSIGT), with Minimal Model
analysis (Bergman et al. 1979; Steil et al. 1993), to derive
quantitative estimates of glucose effectiveness (SG) and
insulin sensitivity (SI). For these subjects, the acute in-
sulin response to glucose (AIR) was computed as the
incremental integrated area under the insulin curve for
the first 8 min of the FSIGT and was used as an index
of insulin secretion. We also computed the disposition
index (DI), the product of SI and AIR, as a resistance-
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Table 1
Phenotypes
DIABETIC INDEX
CASES/SIBLINGS ( )n p 1,175
NONDIABETIC SUBJECTS
Spouses ( )n p 194 Offspring ( )n p 521
Ratio
(Female:Male)
Sex 599:576 132:62 261:260
Mean  SD [Median]
Age (years) 64.2  8.3 [64.8] 61.5  7.7 [61.3] 34.6  7.4 [34.8]
BMI (kg/m2) 29.8  4.8 [29.3] 28.4  4.5 [28.1] 25.9  4.5 [25.3]
WHR .94  .08 [.94] .88  .08 [.88] .86  .08 [.85]
Fasting glucose (mM) 10.2  3.5 [9.6] 5.2  .6 [5.2] 5.1  .6 [5.0]
2-h glucose (mM) … 6.2  1.8 [6.0] 5.3  1.5 [5.2]
Fasting insulin (pM) 111  67 [96] 76  49 [66] 67  35 [60]
2-h insulin (pM) … 427  315 [348] 317  245 [228]
Fasting C-peptide (nM) 1.59  .93 [1.44] … …
SI(EST) (#100) .18  .31 [.11] .35  .32 [.29] .40  .34 [.34]
IRI 12.0  8.1 [10.3] 14.4  8.2 [12.9] 13.2  6.4 [12.3]
IRC .17  .11 [.14] … …
SG (#100 min
1) … 1.65  .57 [1.59] 1.77  .58 [1.70]
SI [#10
5min1/pM) … 5.88  3.41 [5.41] 7.57  4.48 [6.71]
AIR (pM #8 min) … 2,331  1,624 [1,868] 2,188  1,528 [1,897]
DI … 12,244  8,726 [9,983] 14,178  9,163 [12,538]
Table 2
Analyses of Diabetic and Nondiabetic Subjects
Diabetic
Subjects
Nondiabetic
Subjects
BMI • •
WHR • •
Fasting glucose • •
2-h glucose •
Fasting insulin • •
2-h insulin •
Fasting C-peptide •
SI(EST) • •
IRI • •
IRC •
SG •
SI •
AIR •
DI •
corrected index of b-cell function (Bergman et al. 1981;
Kahn et al. 1993).
Empirical Metabolic Indices
Because we did not perform FSIGTs in our diabetic
individuals, we could not scan for loci linked to the
FSIGT-derived measures of insulin resistance and insulin
secretion in these individuals. We attempted to circum-
vent this problem by constructing empirical indices for
insulin resistance and insulin secretion, using the fasting-
glucose, insulin, and C-peptide measurements from all
our diabetic and nondiabetic subjects. For insulin resis-
tance, we used the index described by Sluiter et al.
(1976): SI(EST) p 1/(glucose # insulin). This empirical
index for insulin resistance, SI(EST), was correlated with
SI from the Minimal Model, in nondiabetic spouses and
offspring (Spearman correlation: ; ).r p .54 P p .0001
Although fasting insulin or C-peptide might be con-
sidered reflections of insulin secretion, these measures
do not account for the variability introduced by the un-
derlying stimulatory effect of the fasting-glucose con-
centration. Thus, we constructed empirical indices for
insulin secretion, as follows: IRI p insulin/glucose and
IRC p C-peptide/glucose. Since our indices for insulin
secretion are derived from fasting measurements, they
likely reflect basal insulin secretion, rather than stimu-
lated insulin secretion. Therefore, compared with the
correlation between SI and SI(EST), AIR was less strongly
correlated with IRI in the nondiabetic spouses and off-
spring (Spearman correlation: ; ).r p .39 P p .0001
Fasting C-peptide was not measured in nondiabetic sub-
jects; therefore, a comparison between AIR and IRC was
not possible. However, given the equimolar relationship
between insulin and C-peptide (Rubenstein et al. 1969),
we would expect the correlation to be similar.
Medication Exclusions
Prior to clinical testing, all subjects, diabetic and non-
diabetic, were asked to refrain from taking any of their
prescription medications during the day of clinic visits.
Data for any subject who, on the morning of blood
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Table 3
MLS 1.18 in Diabetic Subjects
Position
(cM) Trait Covariatesa MLS Pb
Chromosome 1:
98.0 BMI 1 1.19 .0097
164.5 IRC 1 1.45 .0049
Chromosome 3:
21.0 IRI 2 1.39 .0057
53.0 IRC 2 3.13 .0001
56.0 BMI 1 1.19 .0097
58.0 C-peptide 2 2.26 .0006
Chromosome 4:
28.5 IRI 1 1.38 .0058
Chromosome 5:
198.0 BMI 1 1.24 .0084
Chromosome 7:
74.5 C-peptide 2 1.63 .0031
74.5 IRC 2 1.76 .0022
101.0 Insulin 2 1.94 .0014
Chromosome 8:
103.5 Glucose 1 1.23 .0042
Chromosome 9:
0.0 Insulin 1 1.32 .0068
5.0 C-peptide 2 1.36 .0061
Chromosome 11:
89.5 Insulin 2 2.07 .0010
91.0 IRI 2 2.32 .0005
Chromosome 13:
7.0 BMI 1 2.95 .0002
39.5 C-peptide 1 1.18 .0098
41.0 Insulin 1 1.22 .0090
Chromosome 14:
96.5 SI(EST) 2 1.19 .0096
102.0 Insulin 1 2.67 .0008
Chromosome 17:
0.0 SI(EST) 2 1.54 .0039
Chromosome 19:
8.5 BMI 1 1.45 .0049
73.5 SI(EST) 1 1.82 .0019
a 1 p age and sex; 2 p age, sex, and BMI.
b For MLS 2.50, empirical P values from simulations are
reported. For details, see the Subjects and Methods section.
sampling, took medications likely to affect the outcome
of interest were excluded from analyses.
QTL Linkage Analysis
We used a multipoint variance-components approach
for our QTL genome scan (Amos 1994; Blangero and
Almasy 1997). We modeled the mean level of each quan-
titative-trait value as a linear function of age and sex.
Because obesity is a known risk factor for type 2 diabetes
(Lillioja and Bogardus 1988; Ohlson et al. 1988), and
because genes for obesity may overlap with those for
type 2 diabetes, we also tested models with additional
adjustment for either body-mass index (BMI) or waist-
to-hip ratio (WHR). Both BMI and WHR were also
examined as quantitative traits. For this article, we chose
to report only those results from the age- and sex-ad-
justed and age-, sex-, and BMI-adjusted traits. We report
results from either the unadjusted trait or the additional
adjustment for WHR only when they provide notably
stronger evidence for linkage.
The total variance (j2) for a quantitative trait was
partitioned into components due to a major gene ( ),2jmg
additive polygenes ( ), and individual-specific envi-2jpg
ronment ( ): . Similarly, the co-2 2 2 2 2j j p j  j  je mg pg e
variance between the trait values for two noninbred
individuals i and j was defined as Cov(X ,X ) pi j
. Here, IBDij is the estimated
2 2 2j IBD  j 2f  j dmg ij pg ij e ij
proportion of genes shared identical by descent (IBD)
by i and j at the putative major gene; fij is the kinship
coefficient, the probability that alleles drawn at random
from individuals i and j, at a given locus, are IBD (Jac-
quard 1974); and if and if .d p 1 i p j d p 0 i ( jij ij
All data were transformed to approximate univariate
normality prior to analysis. Square root (in the case of
C-peptide, DI, SI(EST), IRI, and IRC) or natural-logarithm
transformations (in the case of fasting and 2-h glucose
and insulin, SI) were used for most variables. Exceptions
were SG (y
0.25) and AIR (y0.185). Also, we used the natural
log–transformed BMI and WHR values in the mean
model, since their distributions were skewed. Maxi-
mum-likelihood parameter estimates were derived by use
of the computer program USERFQTL. This software
merges the IBD-estimation algorithm from SIBLINK
(Hauser and Boehnke 1998) with the variance-compo-
nents algorithm from the computer program FISHER
(Lange et al. 1988). The presence of a major trait gene
was assessed at each evaluation point along the genome,
by the likelihood-ratio statistic (L), in which we com-
pared models with the major-gene variance component
set to 0 against those in which it was allowed to be
positive. Because of the one-sided nature of this test, L
is asymptotically distributed as a 50:50 mixture of x2
on 1 df and a point mass at 0 (Self and Liang 1987), so
that the P values are half as large as those in the two-
sided case. For presentation purposes, in this article we
have converted L to maximum LOD scores (MLSs).
Analyses were performed on nuclear families, with
diabetic siblings analyzed separately from nondiabetic
spouses and offspring, because of differences in trait dis-
tributions. In the case of nondiabetic-subject analyses,
in which a diabetic index case or sibling served as a
parent in the nuclear-family structure, the diabetic in-
dividual’s genotype information was included for the
purpose of IBD estimation, but his/her quantitative trait
values were set to missing, so as not to contribute to the
variance-covariance structure. In addition, we per-
formed analyses on the offspring only, to protect against
possible violations of model assumptions by inclusion
of the nondiabetic spouses. In the majority of cases, the
offspring-only analyses gave results similar to those of
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Table 4
MLS 1.18 in Nondiabetic Subjects
Position
(cM) Trait Covariates MLS P
Chromosome 1:
131.5 SG 1 1.41 .0054
165.5 Glucose 1 1.67 .0028
265.0 Insulin 2 1.37 .0060
267.0 2-h insulin 2 2.63 .0003
Chromosome 2:
97.0 SG 1 1.22 .0090
145.0 SI 2 1.43 .0051
Chromosome 3:
38.0 DI 1 1.31 .0071
40.0 Glucose 2 2.22 .0008
65.0 BMI 1 2.16 .0008
Chromosome 6:
41.0 Glucose 2 1.92 .0015
69.0 BMI 1 1.18 .0100
119.5 Insulin 1 1.85 .0019
119.5 IRI 1 2.02 .0012
Chromosome 7:
0.0 Glucose 2 1.24 .0085
82.0 BMI 1 2.21 .0007
Chromosome 8:
13.0 DI 1 1.32 .0069
135.5 BMI 1 2.29 .0006
Chromosome 9:
51.0 2-h insulin 2 1.19 .0097
114.5 AIR 2 1.97 .0013
Chromosome 10:
12.5 Glucose 1 1.23 .0087
21.0 AIR 2 3.11 .0001
102.0 SG 1 1.63 .0031
Chromosome 12:
129.5 BMI 1 1.36 .0061
Chromosome 13:
62.0 IRI 2 1.37 .0059
65.5 2-h insulin 1 2.86 .0002
Chromosome 14:
0.0 DI 1 1.19 .0096
1.0 SI 2 1.46 .0047
5.5 2-h insulin 2 1.51 .0042
25.5 Glucose 1 2.01 .0012
Chromosome 15:
74.0 SI(EST) 1 1.18 .0100
74.0 Insulin 2 1.53 .0040
75.0 IRI 2 1.48 .0045
Chromosome 16:
42.0 SI(EST) 1 1.47 .0046
44.5 IRI 2 1.89 .0016
45.0 Insulin 2 1.71 .0025
65.0 2-h insulin 1 1.28 .0077
78.0 SG 1 1.33 .0067
Chromosome 17:
0.0 2-h glucose 2 1.44 .0051
9.0 Insulin 1 2.97 .0001
9.0 2-h insulin 2 2.71 .0006
9.0 SI(EST) 1 2.25 .0006
9.0 IRI 1 3.20 !.0001
46.5 SG 1 1.27 .0077
Chromosome 18:
36.0 WHR 1 2.61 .0003
Chromosome 19:
72.5 2-h insulin 1 1.39 .0057
74.0 IRI 1 1.52 .0040
75.5 Insulin 1 1.38 .0058
76.5 SI(EST) 1 1.94 .0014
79.5 2-h glucose 1 1.40 .0065
94.5 Glucose 1 2.05 .0011
Chromosome 20:
9.5 2-h glucose 2 1.76 .0022
19.5 IRI 1 1.19 .0095
Chromosome 22:
0.0 2-h insulin 1 2.08 .0010
NOTE.—Data are as defined in the footnotes to table 3.
the nondiabetic spouses and offspring together. Thus,
we report only results from the combined nondiabetic
spouse and offspring analyses.
We made the a priori decision to analyze diabetic and
nondiabetic subjects separately, because of differences in
the trait distributions in the two groups. These differ-
ences are likely due either to the traits being influenced
by the diabetes per se or to the variety and variable
efficacy of treatment regimens that the diabetic subjects
were undergoing at the time of testing. However, for
several traits, we observed overlapping linkage signals
between diabetic and nondiabetic subjects. For these sit-
uations, we combined the diabetic and nondiabetic trait
data and examined whether the trait distributions were
approximately univariate normal (data not shown). If
the combined trait distribution was approximately uni-
variate normal, we combined the data from diabetics
and nondiabetics in a single joint analysis. In these joint
analyses, we included disease affection status as an ad-
ditional covariate in our models. In addition, because
USERFQTL limits the analysis to nuclear families, the
extended family structure was broken down into indi-
vidual nuclear families for analysis.
Statistical Significance
Lander and Kruglyak (1995) have proposed guidelines
for interpretation of linkage results from genomewide
scans. As such, their recommendations are applicable
only for interpretation on a genomewide level. Further-
more, their simulations were designed to assess linkage
based on affection status and not for QTLs. Therefore,
we performed computer simulations to assess pointwise
statistical significance more accurately for our most in-
teresting results (MLS 2.50). In each replicate sample,
marker genotypes were simulated under the null hy-
pothesis of no linkage, with the observed nuclear-family
structures and phenotypes. Simulations of 10,000 or
100,000 replicates were generated, and the resulting
LOD-score distribution was used to generate empirical
P values. In general, the empirical P values were slightly
larger than the nominal P values, suggesting that the
nominal values tend to slightly overstate the evidence
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for linkage (data not shown). Thus, for MLS 2.50 we
report the empirical P values from our simulations.
Results
The mean, median, and SD of trait values for subjects
analyzed for this QTL genome scan are shown in table
1. Table 2 provides a breakdown of analyses, by quan-
titative trait and group. As noted above, neither FSIGT-
derived traits for diabetic subjects nor fasting C-peptide
and, consequently, IRC, for nondiabetic subjects was
available for analysis.
Tables 3 and 4 summarize MLS 1.18 (correspond-
ing to ) for diabetic and nondiabetic subjects,P ! .01
respectively. If more than one model yielded a result
greater than this cutoff for a given trait, we report only
the result with the highest MLS. For 13% of the results
reported in tables 3 and 4, one of the alternative models
using different covariates yielded an MLS that was both
either lower or higher than the value reported in the
table and above the 1.18 MLS cutoff value.
Diabetic Subjects
In the analyses of our diabetic subjects, the stron-
gest evidence for QTL linkage was observed on chro-
mosomes 3 and 13, for IRC and BMI, respectively (fig.
1). On chromosome 3 (fig. 1A), the MLS for age-,
sex-, and BMI-adjusted IRC was 3.13 at 53.0 cM, between
markers D3S1266 and D3S1768, and had a 1-LOD sup-
port interval of 44.0–67.0 cM. As might be expected,
because it is a component of IRC, age-, sex-, and BMI-
adjusted fasting C-peptide also showed evidence for link-
age (MLS p 2.26) in the same region of chromosome 3,
and it yielded a maximum at 58.0 cM near marker
D3S1768.
On chromosome 13 (fig. 1B), the MLS for BMI
was 3.28 at 5.0 cM, between markers D13S175 and
D13S221, and had a 1-LOD support interval of
0.0–16.0 cM. With adjustment for age and sex, this sig-
nal dropped to an MLS of 2.95 at 7.0 cM. There were
no other linkage peaks in this region of the chromosome,
for any of the other traits. A second region along chro-
mosome 13 (fig. 1B) showed more-modest evidence for
linkage to fasting insulin (MLS p 1.52 at 41.0 cM),
SI(EST) (MLS p 1.47 at 41.5 cM), and age-, sex-, and
WHR-adjusted fasting C-peptide (MLS p 1.23 at 40
cM). All three signals maximized near marker D13S263.
Other noteworthy results include those for age- and
sex-adjusted fasting insulin on chromosome 14 (MLS p
2.67 at 102.0 cM, near marker D14S95), as well as
both IRI (MLS p 2.32 at 91.0 cM, near D11S1311) and
age-, sex-, and BMI-adjusted fasting insulin, on chro-
mosome 11. The MLS curve for fasting insulin maxi-
mized at 90.0 cM (MLS p 2.26 near D11S1311), and
there was a secondary peak at 53.5 cM (MLS p 1.52).
When SI(EST) was examined, this secondary peak showed
evidence for linkage (MLS p 1.68). Given that SI(EST) is
derived on the basis of fasting insulin, this suggests that
on this chromosome there may be a QTL involved in
some complex interaction between insulin and glucose.
Nondiabetic Subjects
In the analysis of the nondiabetic spouses and off-
spring, the strongest evidence for linkage was observed
on chromosomes 10, 13, and 17 (fig. 2). On chromo-
some 10 (fig. 2A), the MLS for age-, sex-, and BMI-
adjusted AIR was 3.11 at 21.0 cM, near marker
D10S1720, with a 1-LOD support interval of 13.0–27.5
cM. Fasting glucose also showed a weaker linkage peak
in the same region (MLS p 1.38 at 21.0 cM). Unad-
justed fasting insulin and the empirical indices IRI, IRC,
and SI(EST) all showed very modest linkage peaks (MLS
p 0.58–0.89) in the same region (data not shown).
On chromosome 13, the MLS for age- and sex-ad-
justed 2-h insulin was 2.86 at marker D13S156 at 65.5
cM (fig. 2B); however, the 1-LOD support interval was
very wide (50.0–76.5 cM). Age-, sex-, and BMI-adjusted
IRI also showed evidence for linkage in the same region
(MLS p 1.37 at 62.0 cM). On chromosome 17 (fig.
2C), age- and sex-adjusted IRI showed the strongest ev-
idence for linkage, with MLS p 3.20 at 9.0 cM (1-LOD
support interval 4.0–15.0 cM), near marker D17S1832.
Not surprisingly, age- and sex-adjusted fasting insu-
lin (MLS p 2.97) and SI(EST) (MLS p 2.25) both showed
evidence for linkage in this region. However, age-, sex-,
and BMI-adjusted 2-h insulin also showed evidence for
linkage at the same location (MLS p 2.71), with a 1-
LOD support interval of 0.5–13.5 cM (fig. 2C). Other
noteworthy results in our nondiabetic subjects include
2-h insulin, on chromosome 1 (MLS p 2.70 at 270.0
cM); BMI, on chromosome 3 (MLS p 2.52 at 64.0 cM);
age- and sex-adjusted WHR, on chromosome 18 (MLS
p 2.61 at 36.0 cM); and age-, sex-, and WHR-adjusted
2-h insulin, on chromosome 22 (MLS p 2.70 at 0.0
cM).
Overlap of Results for Diabetic and Nondiabetic
Subjects
We observed some regions where evidence for linkage
to a specific quantitative trait overlapped between dia-
betic and nondiabetic subjects. Specifically, on chro-
mosome 3 we observed a stronger signal (MLS p 2.52
at 64.0 cM) for BMI in our nondiabetic subjects and a
weaker signal in the same proximity in our diabetic sub-
jects (MLS p 1.19 at 56.0 cM), after adjustment for
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Figure 1 A, MLS curves for age-, sex-, and BMI-adjusted IRC and for age-, sex-, and BMI-adjusted fasting C-peptide, for chromosome
3 in diabetic subjects. B, MLS curves for results for chromosome 13 in diabetic subjects. Unadjusted BMI showed the strongest evidence for
linkage. However, a cluster of other traits—fasting insulin; SI(EST); and age-, sex-, and WHR-adjusted fasting C-peptide—showed weaker evidence
for linkage at a different locus. Marker names and positions are given at the top of each graph.
age and sex. We also observed a similar situation with
SI(EST) on chromosomes 17 and 19. For these chromo-
somes, we repeated QTL linkage analyses for these traits,
combining data from both groups in a joint analysis.
In the joint analysis of all subjects for BMI without
adjustment for covariates on chromosome 3, we ob-
served an MLS of 3.43 at 59.5 cM (fig. 3A); when we
adjusted for age and sex, the MLS dropped to 2.83.
Similarly, for SI(EST) on chromosome 17, when we com-
bined our diabetic and nondiabetic subjects in a joint
analysis, we observed an MLS of 3.61 at 0.0 cM, after
adjusting for age, sex, and BMI (fig. 3B). The strong
telomeric signal suggests the need for additional markers
in this region, to refine our linkage signal. For chro-
Figure 2 A, MLS curves for age-, sex-, and BMI-adjusted AIR and for fasting glucose, for chromosome 10 in nondiabetic subjects. B,
MLS curves for age- and sex-adjusted 2-h insulin and for age-, sex-, and BMI-adjusted IRI, for chromosome 13 in nondiabetic subjects. C,MLS
curves for age- and sex-adjusted IRI, age- and sex-adjusted fasting insulin, for age-, sex-, and BMI-adjusted 2-h insulin, and for age- and sex-
adjusted SI(EST), for chromosome 17 in nondiabetic subjects.
Figure 3 A, MLS curves for age- and sex-adjusted BMI in diabetic subjects and for BMI in nondiabetic subjects, for chromosome 3.
When data from both groups are analyzed jointly, BMI shows a strong signal at 59.5 cM, with an MLS of 3.43. B, MLS curves for age-,
sex-, and BMI-adjusted SI(EST) in diabetic subjects and for age- and sex-adjusted SI(EST) in nondiabetic subjects, for chromosome 17. Joint analysis
of age-, sex-, and BMI-adjusted SI(EST) shows a stronger signal (MLS p 3.61) at the p-terminus. C, MLS curves for age- and sex-adjusted SI(EST),
in both diabetic and nondiabetic subjects, for chromosome 19. Joint analysis of age-, sex-, and WHR-adjusted SI(EST) shows a stronger signal
(MLS p 2.80) at 74.5 cM.
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mosome 19, the joint analysis yielded an MLS of 2.80
at 74.5 cM after adjustment for age, sex, and WHR (fig.
3C).
There were other examples of overlapping signals
across traits. On chromosome 1, the signal for age- and
sex-adjusted IRC in the diabetic subjects (MLS p 1.61)
and fasting glucose for the same adjustment in the non-
diabetics (MLS p 1.66) both maximized in the same
region (∼165 cM). Similarly, on chromosome 3, age-,
sex-, and BMI-adjusted fasting C-peptide in the diabetics
(MLS p 2.26) and age- and sex-adjusted BMI in the
nondiabetics (MLS p 2.52) maximized in close prox-
imity, at 58.0 and 64.0 cM, respectively. Chromosome
19 showed a particularly interesting set of four out-
comes: the evidence for linkage to age- and sex-adjusted
SI(EST) in diabetic subjects (MLS p 1.82 at 73.5 cM)
overlapped with those for 2-h insulin (MLS p 1.59 at
71.0 cM) in the nondiabetic subjects, age- and sex-ad-
justed SI(EST) (MLS p 1.94 at 76.5 cM) in the nondiabetic
subjects, and age- and sex-adjusted IRI (MLS p 1.52 at
74.0 cM) in the nondiabetic subjects.
Discussion
Type 2 diabetes has all the characteristics of a complex
disorder: convincing evidence for a genetic component,
ambiguous mode of inheritance, strong environmental
component, and likely multiple genes of varying effect
that work independently and/or in concert (Rich 1990;
Ghosh and Schork 1996). The difficult task of identi-
fying the susceptibility genes is complicated by the fact
that the interaction of these factors results in a variety
of disease etiologies. Thus, although, because of clearly
defined diagnostic criteria (National Diabetes Data
Group 1979; World Health Organization 1985), indi-
viduals can be identified as having type 2 diabetes, not
all individuals who eventually develop type 2 diabetes
follow the same path toward disease, nor will they fol-
low the same progression toward disease complications.
These complex features may account for why, despite
the large number of groups performing genomic scans
for type 2 diabetes (Hanis et al. 1996; Mahtani et al.
1996; Hanson et al. 1998; Imperatore et al. 1998; Prat-
ley et al. 1998; Duggirala et al. 1999; Elbein et al. 1999;
Ghosh et al. 1999; Ehm et al. 2000), there have been,
until recently, no published reports of a successful clon-
ing and identification of a major susceptibility gene.
However, recently the chromosome 2 locus linked to
type 2 diabetes in Mexican Americans, also known as
“NIDDM1” (Hanis et al. 1996), has been cloned and
identified as calpain-10, a calpain-like cysteine protease
(Horikawa et al. 2000).
In this article and the companion article (Ghosh et
al. 2000 [in this issue]), we have reported the initial
results of a genomewide scan for linkage to diabetes
and diabetes-related quantitative traits in the FUSION
study. In the companion article (Ghosh et al. 2000 [in
this issue]), we have reported results from our genome-
wide scan of affected sibling pairs sampled from the
population of Finland. Given the expected difficulties
in doing a genome scan for a complex disease, we aug-
mented our ASP linkage results by doing disease-by-
marker association analysis, ordered-subsets linkage
analysis of the disease status data, and QTL linkage
analysis of our quantitative-trait data. In this discussion,
we focus on the results from our QTL genome scan but
also draw on results from our other analyses, where our
evidence for a possible diabetes-susceptibility gene may
be the strongest.
The goal of QTL linkage analysis is to identify loci
that influence specific quantitative traits; in our study,
the traits that we examined are also intimately associ-
ated with type 2 diabetes. Through this approach, we
hoped to identify QTLs that might also act as diabetes-
susceptibility loci. We identified along the genome sev-
eral regions that may contain QTLs. In our analytical
strategy, we chose to analyze data from diabetic and
nondiabetic subjects separately. There were two reasons
for taking this approach. First, the characteristics of the
trait distribution between diabetic and nondiabetic sub-
jects tended to be different. This likely reflects the pos-
sibility that the trait may behave differently in diabetic
individuals, because of disease-induced alterations in
physiology and/or biochemistry. In addition, 190% of
our diabetic volunteers were being treated for their dis-
ease through pharmacological intervention, and a large
proportion of the remainder were treated via lifestyle
modification—that is, changes in diet and/or physical
activity. Thus, trait information in these subjects is likely
to be confounded by these treatment effects.
Despite these potential differences, we did observe
overlapping signals for certain traits across the two
groups. We further investigated these traits by combin-
ing data from diabetic and nondiabetic subjects after
examining the trait distribution of the joint data. In the
joint analyses, we observed substantial increases in some
of our overall MLSs (fig. 3).
A secondary consideration is the issue of overlapping
linkage signals across different traits. We found these
overlaps of particular interest, since many of the traits
that we examined in FUSION, although clinically or
physiologically important, still reflect the net integrat-
ed effect of multiple downstream biochemical events.
Furthermore, because many of these traits are part of
the endocrine hormone–feedback regulatory system, it
would not be unusual to see a single locus having plei-
otropic effects on two or more traits. Thus, we believe
that overlapping signals across traits should be carefully
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evaluated, taking into account whether such clustering
of traits tells a coherent story.
A large proportion of our linkage results involved
traits associated with b-cell function: fasting insulin,
fasting C-peptide, 2-h insulin, and AIR. This suggests
that genes associated with b-cell function may be ex-
erting the strongest genetic effects in the population that
we studied, and it is consistent with our observation
that, in our sample, heritability for secretion-related
traits was stronger than that for insulin resistance–
related traits (Watanabe et al. 1999). This pattern was
also found in a twin study in the same population (Leh-
tovirta et al. 2000).
Both the National Institutes of Health (NIH) group
in Phoenix that is studying the Pima Indians (Pratley et
al. 1998) and the group studying the Old Order Amish
(St. Jean et al. 1999) have completed QTL genome scans
for type 2 diabetes–related quantitative traits, and the
Phoenix group has completed linkage analyses for di-
abetic nephropathy and retinopathy (Imperatore et al.
1998). Also, several groups have reported QTL linkage
results for specific chromosomes (Thompson et al. 1995;
Duggirala et al. 1996, 1999; Stern et al. 1996; Comuz-
zie et al. 1997). In what follows, we note regions along
the genome where evidence for linkage in our QTL ge-
nome scan appears to overlap with evidence reported
by these different studies and where results from our
own ASP linkage analyses provide additional evidence
for regions potentially harboring type 2 diabetes–sus-
ceptibility genes.
On chromosome 3 in Pima Indians, two peaks for
fasting insulin (MLS p 1.30 at 35 cM andMLS p 1.25
at 45 cM) that flank our linkage peak (MLS p 2.22)
for fasting glucose at 40 cM in nondiabetic subjects have
been reported (Pratley et al. 1998). Also, the GENNID
study recently reported evidence for linkage (MLS p
3.91) to type 2 diabetes in Mexican Americans, at
marker D3S2432 (∼50 cM) (Ehm et al. 2000). We also
have observed weaker linkage signals for BMI (MLS p
1.27 at 55.0 cM) in our diabetic subjects and for both
AIR (MLS p 1.12 at 47.0 cM) and DI (MLS p 1.31
at 38.0 cM) in our nondiabetic subjects. This clustering
of insulin secretion–related traits in our sample suggests
that this QTL may be involved in the regulation of b-
cell function.
The gene for peroxisome-proliferator-activator recep-
tor-g2 (PPARG [MIM 601487]) is near this region of
chromosome 3. PPARG plays an important role in adi-
pogenesis and insulin sensitization (Auwerx 1999). Re-
cent reports, including our own study (J. A. Douglas, M.
R. Erdos, R. M. Watanabe, A. Braun, C. L. Johnston, P.
Oeth, K. L. Mohlke, T. T. Valle, C. Ehnholm, T. A. Buch-
anan, R. N. Bergman, F. S. Collins, M. Boehnke, and J.
Tuomilehto, unpublished data), have shown an associ-
ation between the presence of the Pro12Ala polymor-
phism in PPARG and both type 2 diabetes (Deeb et al.
1998) and obesity (Beamer et al. 1998).
We also observed linkage signals proximal to the
PPARG region. These include fasting C-peptide (MLS
p 2.26 at 58.0 cM) and IRC (MLS p 3.13 at 53.0 cM)
in our diabetic subjects and BMI (MLS p 2.52 at 64.0
cM) in our nondiabetic subjects. In Pima Indians, peaks
for fasting insulin (MLS p 1.22 at 188 cM [Pratley et
al. 1998]) and for diabetic nephropathy (MLS p 2.03
at 181.1 cM [Imperatore et al. 1998]) have been re-
ported near the signal that we found for SI(EST) (MLS p
1.59) at 196 cM. This region includes the gene for so-
matostatin (SST [MIM 182450]).
The Phoenix group also has reported, on chromo-
some 6, possible linkage to fasting glucose (MLS p
1.79 at 41 cM [Pratley et al. 1998]), which coincides
with our evidence for linkage (MLS p 1.92) for the
same trait and chromosomal location (table 4) in our
nondiabetic subjects. Stern et al. (1996) have reported
linkage to fasting glucose, on chromosome 6 at D6S300,
∼50 cM away from the location of our linkage peak,
toward the q-terminus. This 40–50-cM region of chro-
mosome 6 includes a variety of plausible candidate
genes, including those for the major histocompatibility
complex, tumor necrosis factor-a (TNF [MIM
191160]), and glucagon-like peptide-1 receptor (GLP1R
[MIM 138032]).
In our nondiabetic subjects, we also had, for both
fasting insulin (MLS p 1.85 at 119.5 cM) and IRI (MLS
p 2.02 at 119.5 cM), interesting QTL results that over-
lapped with those of our ASP-based linkage analysis
(MLS p 0.61-0.78 near 113 cM) (Ghosh et al. 2000
[in this issue]). Ordered-subsets analysis revealed two
subsets with strong evidence for linkage to this region:
low age at diagnosis (74 families; MLS p 2.48 at 104.5
cM) and low fasting glucose (94 families; MLS p 3.17
at 117.0 cM). In addition, in our nondiabetic subjects,
we observed weaker QTL linkage results for 2-h insulin
(MLS p 1.16 at 128.0 cM) and SI(EST) (MLS p 1.17 at
125.0 cM). Stern et al. (1996) have reported, near this
region of chromosome 6 in their sample of Mexican
Americans, evidence for linkage to fasting glucose (MLS
p 2.17). Also, linkage to age-adjusted type 2 diabetes
has been reported in this region (Z-score p 1.39 at 128
cM) in the Pima Indians (Hanson et al. 1998).
The Phoenix group has reported evidence for linkage,
on chromosome 9, to both 2-h insulin (MLS p 2.16 at
98 cM [Pratley et al. 1998]) and diabetic nephropathy
(two-point MLS p 1.28 at 114.6 cM [Imperatore et al.
1998]), near our peak (MLS p 1.97 at 114.5 cM) for
AIR. This region includes the genes for muscle and he-
patic fructose-1,6 bisphosphatase (FBP2 [MIM603027]
and FBP1 [MIM 229700]), a key rate-limiting enzyme
for gluconeogenesis.
In the region on chromosome 19 where we observed
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evidence for linkage to multiple traits, Pratley et al.
(1998) have reported linkage to 2-h glucose (MLS p
1.14 at 75 cM). We also observed a weak association
between marker D19S867 at 79.5 cM and affection
status ( ; Ghosh et al. 2000 [in this issue]). ThisP p .05
region includes genes for the muscle form of creatine
kinase (CKM [MIM 123310]), gastric inhibitory pep-
tide receptor (GIPR [MIM 137241]), hepatocyte nu-
clear factor 3g (HNF3G [MIM 602295]), and muscle
glycogen synthase I (GYS1 [MIM 138570]). GYS1 is
the rate-limiting step for glycogen formation in muscle
and has been examined as a candidate gene, by both
Groop et al. (1993) and the Phoenix group (Majer et
al. 1996). Groop et al. (1993) noted a specific allele that
identified a subgroup of their diabetic subjects with both
a strong family history of disease and a higher preva-
lence of hypertension and insulin resistance. In contrast,
Majer et al. (1996) found no mutations in the GYS1
gene or alterations in mRNA expression or enzymatic
activity.
Elsewhere, we have reported, for chromosome 20,
modest QTL results (Ghosh et al. 1999) that overlapped
with the ASP linkage peak toward the p-terminus of the
chromosome. We have since genotyped an additional 5
markers, bringing the total to 43 markers genotyped on
chromosome 20. The information provided by these
markers modestly increased our QTL linkage signals for
2-h insulin (from MLS p 1.06 at 19.0 cM to MLS p
1.09 at 18.5 cM), IRI (from MLS p 1.12 at 19.5 cM
to MLS p 1.19 at 19.5 cM), and 2-h glucose (from
MLS p 1.59 at 9.5 cM to MLS p 1.70 at 9.0 cM).
Finally, on the p-terminus of chromosome 22, the
Phoenix group reports evidence for linkage to high-dose
M-value from the glucose clamp (MLS p 2.12), cor-
responding to our result for 2-h insulin (MLS p 2.70).
We are not aware of any obvious candidate genes in
this region.
We identified other candidate genes that, on the basis
of our QTL genome scan, fall into regions of interest.
Many, if not all, have been examined as candidate genes
in a variety of type 2 diabetes populations. On chro-
mosome 1, the gene for pyruvate kinase (PK1 [MIM
266200]), a key glycolytic enzyme, and the gene for the
G-protein coupled potassium channel (KCNJ9 [MIM
600932], also known as “GIRK3” or “Kir3.3”) fall
within the region in which we observed evidence for
linkage both to IRC in our diabetic subjects (MLS p
1.61) and to fasting glucose in our nondiabetic subjects
(MLS p 1.66). Genes for insulin-like growth fac-
tor–binding proteins 1 and 3 (IGFBP1 [MIM 146730]
and IGFBP3 [MIM 146732]) are near the chromosome
7 region in which we observed results, in diabetic sub-
jects, for fasting C-peptide (MLS p 1.63) and IRC (MLS
p 1.76). IGF-binding proteins regulate IGF activity
and, under some conditions, may play a role in devel-
opment of diabetic complications (Bach and Rechler
1995). Glucokinase (GCK [MIM 138079]), the key
rate-limiting enzyme for glycolysis, is found just prox-
imal to this region, and polymorphisms in this gene are
responsible for MODY-2 (Froguel et al. 1992; Vionnet
et al. 1992) St. Jean et al. (1999) have noted, on chro-
mosome 14, evidence for linkage to fasting glucose
(MLS p 2.00 at 29 cM) and to 2-h glucose (MLS p
2.53 at 22 cM), in large pedigrees from the Old Order
Amish. These results coincide with our fasting-glu-
cose result (MLS p 2.28 at 24.5 cM) in nondiabetic
subjects. The genes for phosphoenolpyruvate carboxy-
kinase 2 (PCK2 [MIM 261650]) and hepatocyte nuclear
factor 3a (HNF3A [MIM 602294]) flank this region of
chromosome 14. Finally, on chromosome 17, genes for
tyrosine kinase nonreceptor 1, glucose transporter 4
(SLC2A4 [MIM 138190]), mitogen-activated protein
kinase kinase 4 (MAP2K4 [MIM 601335]), and aden-
osine A2b receptor (ADORA2B [MIM 600446]) fall
into the region of our linkage peaks for fasting insulin
(MLS p 2.97), 2-h insulin (MLS p 2.71), SI(EST) (MLS
p 2.25), and IRI (MLS p 3.20), at 9.0 cM in our
nondiabetic subjects.
In summary, we report the results from both a type
2 diabetes genome scan (Ghosh et al. 2000 [in this is-
sue]) and an autosomal genome scan for type 2 dia-
betes–related quantitative traits. Our QTL linkage anal-
yses reveal along the genome several regions that may
include genes related to both adiposity and insulin se-
cretion in our Finnish cohort. Furthermore, there is
overlap between our QTL linkage results and results
from our disease status–based linkage results. When we
integrated the results from all of our analyses, we iden-
tified, on chromosomes 1–3, 6, 7, 10, 11, 17, 19, and
20, regions that have evidence for possible diabetes-
susceptibility loci. We have now targeted these regions
for further statistical analyses and/or additional geno-
typing, to further refine our evidence for linkage.
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